Sharon Curran named Rosemont chair

23 July 2025

UK-based Rosemont Pharmaceuticals has appointed a new chair with a wealth of experience in the US pharma market.

Irish-born Sharon Curran (pictured above) will take up the role with Rosemont, a company that manufactures and specializes in novel, Rx oral liquid medicines for patients who have difficulty swallowing due to conditions such as dysphagia, stroke or dementia.

Ms Curran has held extensive senior and executive leadership roles in healthcare including non-executive board positions at businesses across Europe and the USA, notably AbbVie (NYSE: ABBV) in Chicago. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight



More Features in Pharmaceutical